Cargando…

Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review

BACKGROUND: The recently established association between higher levels of DNA-incorporated thioguanine nucleotides and lower relapse risk in childhood acute lymphoblastic leukaemia (ALL) calls for reassessment of prolonged 6-thioguanine (6TG) treatment, while avoiding the risk of hepatotoxicity. OBJ...

Descripción completa

Detalles Bibliográficos
Autores principales: Toksvang, Linea Natalie, Schmidt, Magnus Strøh, Arup, Sofie, Larsen, Rikke Hebo, Frandsen, Thomas Leth, Schmiegelow, Kjeld, Rank, Cecilie Utke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534292/
https://www.ncbi.nlm.nih.gov/pubmed/31125338
http://dx.doi.org/10.1371/journal.pone.0212157
_version_ 1783421382202228736
author Toksvang, Linea Natalie
Schmidt, Magnus Strøh
Arup, Sofie
Larsen, Rikke Hebo
Frandsen, Thomas Leth
Schmiegelow, Kjeld
Rank, Cecilie Utke
author_facet Toksvang, Linea Natalie
Schmidt, Magnus Strøh
Arup, Sofie
Larsen, Rikke Hebo
Frandsen, Thomas Leth
Schmiegelow, Kjeld
Rank, Cecilie Utke
author_sort Toksvang, Linea Natalie
collection PubMed
description BACKGROUND: The recently established association between higher levels of DNA-incorporated thioguanine nucleotides and lower relapse risk in childhood acute lymphoblastic leukaemia (ALL) calls for reassessment of prolonged 6-thioguanine (6TG) treatment, while avoiding the risk of hepatotoxicity. OBJECTIVES: To assess the incidence of hepatotoxicity in patients treated with 6TG, and to explore if a safe dose of continuous 6TG can be established. DATA SOURCES: Databases, conference proceedings, and reference lists of included studies were systematically searched for 6TG and synonyms from 1998–2018. METHODS: We included studies of patients with ALL or inflammatory bowel disorder (IBD) treated with 6TG, excluding studies with 6TG as part of an intensive chemotherapy regimen. We uploaded a protocol to PROSPERO (registration number CRD42018089424). Database and manual searches yielded 1823 unique records. Of these, 395 full-texts were screened for eligibility. Finally, 134 reports representing 42 studies were included. RESULTS AND CONCLUSIONS: We included data from 42 studies of ALL and IBD patients; four randomised controlled trials (RCTs) including 3,993 patients, 20 observational studies including 796 patients, and 18 case reports including 60 patients. Hepatotoxicity in the form of sinusoidal obstruction syndrome (SOS) occurred in 9–25% of the ALL patients in two of the four included RCTs using 6TG doses of 40–60 mg/m(2)/day, and long-term hepatotoxicity in the form of nodular regenerative hyperplasia (NRH) was reported in 2.5%. In IBD patients treated with 6TG doses of approximately 23 mg/m(2)/day, NRH occurred in 14% of patients. At a 6TG dose of approximately 12 mg/m(2)/day, NRH was reported in 6% of IBD patients, which is similar to the background incidence. According to this review, doses at or below 12 mg/m(2)/day are rarely associated with notable hepatotoxicity and can probably be considered safe.
format Online
Article
Text
id pubmed-6534292
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-65342922019-06-05 Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review Toksvang, Linea Natalie Schmidt, Magnus Strøh Arup, Sofie Larsen, Rikke Hebo Frandsen, Thomas Leth Schmiegelow, Kjeld Rank, Cecilie Utke PLoS One Research Article BACKGROUND: The recently established association between higher levels of DNA-incorporated thioguanine nucleotides and lower relapse risk in childhood acute lymphoblastic leukaemia (ALL) calls for reassessment of prolonged 6-thioguanine (6TG) treatment, while avoiding the risk of hepatotoxicity. OBJECTIVES: To assess the incidence of hepatotoxicity in patients treated with 6TG, and to explore if a safe dose of continuous 6TG can be established. DATA SOURCES: Databases, conference proceedings, and reference lists of included studies were systematically searched for 6TG and synonyms from 1998–2018. METHODS: We included studies of patients with ALL or inflammatory bowel disorder (IBD) treated with 6TG, excluding studies with 6TG as part of an intensive chemotherapy regimen. We uploaded a protocol to PROSPERO (registration number CRD42018089424). Database and manual searches yielded 1823 unique records. Of these, 395 full-texts were screened for eligibility. Finally, 134 reports representing 42 studies were included. RESULTS AND CONCLUSIONS: We included data from 42 studies of ALL and IBD patients; four randomised controlled trials (RCTs) including 3,993 patients, 20 observational studies including 796 patients, and 18 case reports including 60 patients. Hepatotoxicity in the form of sinusoidal obstruction syndrome (SOS) occurred in 9–25% of the ALL patients in two of the four included RCTs using 6TG doses of 40–60 mg/m(2)/day, and long-term hepatotoxicity in the form of nodular regenerative hyperplasia (NRH) was reported in 2.5%. In IBD patients treated with 6TG doses of approximately 23 mg/m(2)/day, NRH occurred in 14% of patients. At a 6TG dose of approximately 12 mg/m(2)/day, NRH was reported in 6% of IBD patients, which is similar to the background incidence. According to this review, doses at or below 12 mg/m(2)/day are rarely associated with notable hepatotoxicity and can probably be considered safe. Public Library of Science 2019-05-24 /pmc/articles/PMC6534292/ /pubmed/31125338 http://dx.doi.org/10.1371/journal.pone.0212157 Text en © 2019 Toksvang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Toksvang, Linea Natalie
Schmidt, Magnus Strøh
Arup, Sofie
Larsen, Rikke Hebo
Frandsen, Thomas Leth
Schmiegelow, Kjeld
Rank, Cecilie Utke
Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review
title Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review
title_full Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review
title_fullStr Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review
title_full_unstemmed Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review
title_short Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review
title_sort hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: a systematic review
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534292/
https://www.ncbi.nlm.nih.gov/pubmed/31125338
http://dx.doi.org/10.1371/journal.pone.0212157
work_keys_str_mv AT toksvanglineanatalie hepatotoxicityduring6thioguaninetreatmentininflammatoryboweldiseaseandchildhoodacutelymphoblasticleukaemiaasystematicreview
AT schmidtmagnusstrøh hepatotoxicityduring6thioguaninetreatmentininflammatoryboweldiseaseandchildhoodacutelymphoblasticleukaemiaasystematicreview
AT arupsofie hepatotoxicityduring6thioguaninetreatmentininflammatoryboweldiseaseandchildhoodacutelymphoblasticleukaemiaasystematicreview
AT larsenrikkehebo hepatotoxicityduring6thioguaninetreatmentininflammatoryboweldiseaseandchildhoodacutelymphoblasticleukaemiaasystematicreview
AT frandsenthomasleth hepatotoxicityduring6thioguaninetreatmentininflammatoryboweldiseaseandchildhoodacutelymphoblasticleukaemiaasystematicreview
AT schmiegelowkjeld hepatotoxicityduring6thioguaninetreatmentininflammatoryboweldiseaseandchildhoodacutelymphoblasticleukaemiaasystematicreview
AT rankcecilieutke hepatotoxicityduring6thioguaninetreatmentininflammatoryboweldiseaseandchildhoodacutelymphoblasticleukaemiaasystematicreview